Organoids

About Organoids

Organoid Sciences is a premier South Korean Deep Tech biotechnology firm founded in 2018 by Dr. Jongman Yoo, an associate professor at CHA University and a global authority on organoid research. The company stands as a leader in regenerative medicine and drug discovery by utilizing 3D human organoids—functional, miniaturized versions of human organs—that provide a high-fidelity alternative to traditional animal testing. The company's commercial strategy is built on two primary pillars: ATORM, a platform focused on developing organoid-based regenerative therapeutics for intractable diseases, and ODISEI, an advanced screening solution for the pharmaceutical and cosmetic industries. Since its launch in 2021, ODISEI has revolutionized preclinical evaluations by predicting human biological responses with unprecedented accuracy. Furthermore, the company’s PODOTX platform offers critical insights into immunotherapy sensitivity, enabling true precision oncology. With over 49 billion KRW (approx. $38M) in funding from top-tier investors like Aju IB and Korea Development Bank, Organoid Sciences has established GMP-certified CDMO facilities and successfully transitioned to a public entity on the KOSDAQ exchange. Recognized as a "National Advanced Strategic Technology" provider, the firm is a vital asset for NIF Health Security and NIF Crisis Preparedness, ensuring South Korea’s independence in developing next-generation biopharmaceuticals and rapid-response medical countermeasures.